Unmet Need

• Hepatoblastoma is the most common primary liver tumor in children (0–4 years).
• Annual incidence: 1.8 cases per million.
• Current treatments (surgery, chemotherapy, liver transplantation) have ~12% relapse rate.
• Relapsed tumors often show chemoresistance, linked to poor prognosis.

Current Therapeutics Options:

Modality	Role	Limitations
Surgical resection	Gold standard in localized disease; best chance for cure when complete removal is possible.	Many tumors are unresectable at diagnosis due to size, multifocality, or involvement of critical structures.
Liver transplantation	For unresectable but liver-confined disease; can achieve cure in some cases.	Donor shortage, surgical risk, need for lifelong immunosuppression, high cost.
Chemotherapy (cisplatin-based regimens etc.)	Used pre-operatively to shrink tumors; post-operatively to reduce recurrence; also in metastatic disease.	Toxicity; some tumors are or become resistant; side effects in young children.
Supportive care monitoring	For small/stable lesions or when treatment is not tolerated.	Does not reliably prevent progression or relapse; not curative.

Our Solution

We have developed a proprietary siRNA therapeutic that precisely silences a oncogenic driver of hepatoblastoma. Key benefits:

• Precision targeting of liver tumor cells.
• Enhanced safety – reduced systemic exposure vs. conventionalnanoparticles.
• Chemoresistance bypass by silencing survival and resistancepathways.
• Adaptability – compatible with patient-specific oncogene profiles.
• Clinically validated platform – GalNAc conjugation already proven in approved siRNA drugs.

Technology Highlights

• Mechanism: siRNA triggers RNA interference to silence disease-causing mRNAs.
• Delivery: Nanoparticle/lipid carriers ensure liver-targeted action.
• Versatility: Applicable in both primary and relapsed hepatoblastoma.
• Personalization: Customizable to patient-specific tumor profiles.

Collaboration Opportunities

We are seeking partnerships with:

• Pharma companies (pediatric oncology, RNA therapeutics)
• Clinical Research institutions (for preclinical & clinical validation)
• Investors (to accelerate translational development)

EXPORT INFO

Background

Small Ubiquitin-like Modifier (or SUMO) proteins are covalently attached to other proteins in cells to modify their function, also called SUMOylation. This is mediated by a multistep enzymatic cascade, similar to ubiquitination. SUMOylation is a dynamic process that can change the subcellular localization, stability, or interaction partners of modified proteins within cells. SUMOylation has been linked to diverse cellular pathways and its deregulation has been linked to many types of disease (inflammation, cancer, cardiovascular disease, etc.). SUMO modulates cellular functions like: 1) Changes in subcellular localization, 2) Alteration of protein-DNA binding affinity, 3) Alteration of protein-protein interaction, 4) Stabilization of target, 5) Promoting proteasomal degradation.

Current Options. solation of proteins modified by SUMO can be achieved by the use of 1) antibodies that specifically react with the SUMO protein-target protein conjugates and 2) the overexpression of tagged-SUMO. Both methods have drawbacks including expense, need for expertise, and altered physiology due to need for overexpression or transgenesis.

Technology

Our technology allows the affinity purification of SUMO and SUMO-conjugated proteins by the use of engineered proteins comprising tandem arrangements of SUMO interacting motifs, connected by flexible linkers.

Application

Our high affinity SUMO traps technology can be applied as a molecular trap to isolate the pool of SUMOylated proteins in a given tissue or cell type. It can facilitate the isolation of SUMO- and polySUMO-modifed proteins from cells and tissues for downstream analysis. It could be used as a biological and medical research tool to study.

SUMOylation during development, progression of disease, or in response to drug treatment. These engineered proteins allow the capture and analysis of SUMOylated proteins in vitro or from cells/tissues, facilitating the study of post-translational mechanisms that connect signaling cascades with effector functions. They may be useful for the development and implementation of novel screens for biomarkers and have potential for diagnostic use.

Advantages

SUMOtraps show a high specificity for SUMOylated proteins, especially those undergoing polySUMOylation. This technology overcomes the need for overexpressed tagged-SUMO, which might alter the SUMOylation equilibrium of the cells, and does not rely on expensive antibodies or complicated isolation protocols. SUMOylated proteins can isolated from patient-derived tissues as well as cellular and animal models.

NEED Ready for out-licensing.

EXPORT INFO

This patented technology provides a reliable method to determine endometrial receptivity using specific miRNA expression signatures. The invention enables clinicians to identify the optimal timing for embryo transfer and select patients who may benefit from therapies to restore receptivity, significantly improving success rates in assisted reproduction techniques (ART).

Key Features & Technical Details

• Innovation: First non-invasive, miRNA-based diagnostic tool for assessing endometrial receptivity.
• Method: Detection and quantification of specific miRNA signatures in biological samples (e.g., endometrial fluid).
• Diagnostic Output:
  • Receptive endometrium
  • Non-receptive endometrium
• Validation: Robust predictive models (AUC ~80–90%).
• Implementation: Compatible with qPCR, RT-qPCR, hybridization arrays, next-generation sequencing, and other nucleic acid detection methods.

Applications

• Clinical Use in IVF/ART:
  • Precise determination of the implantation window.
  • Improved selection of embryo transfer timing.
  • Patient stratification for therapies restoring receptivity.
• Diagnostic Kits: Ready-to-use reagents for fertility clinics and IVF centers.
• Therapeutic Guidance: Identify women requiring personalized treatment to enhance implantation success.

Advantages

• Accurate and reproducible
• Higher implantation and pregnancy rates in ART
• Reduces unnecessary embryo transfers and associated costs
• Applicable to large-scale fertility programs

Collaboration Opportunities

We are seeking partnerships with:

• Reproduction Clinics with Diangostics componente
• Clinical Research institutions (for clinical validation in real environment)

EXPORT INFO

Technology Overview

α-synCas is a synthetic nuclease engineered to overcome the limitations of naturally occurring CRISPR-Cas systems. Unlike Cas9, Cas12, or Cas13, α-synCas shows broad substrate versatility, enabling the cleavage of dsDNA, ssDNA, and ssRNA. This makes it a unique platform for both detection and genome engineering applications.

Key Features & Advantages

• Novelty: No natural homologs, representing a new nuclease family.
• Substrate Flexibility: Targets and cleaves DNA (ds/ss) and RNA.
• Trans-Cleavage Activity: Non-specific nucleic acid degradation upon activation.
• No PAM Requirement: Broader target accessibility.
• crRNA Versatility: Compatible with guide RNAs from multiple Cas systems.
• Autonomous Processing: Able to process pre-crRNAs.

Applications

• Nucleic Acid Detection: Development of broad diagnostic platforms.
• Genome Editing: Expanded targeting range and flexibility.
• Gene Regulation: Tools for transcriptional and post-transcriptional control.
• Therapeutics: Potential antiviral and genetic disease applications.

Need Not exclusive Licensee.

EXPORT INFO

This patented technology leverages the unique physicochemical and bioactive properties of saponins to develop novel applications in health, food, and industrial sectors. The invention enables efficient extraction, formulation, and use of saponins as natural, multifunctional agents with both commercial and therapeutic potential.

Key Features & Technical Details

• Source & Extraction: Optimized process for obtaining high-purity saponins from plant or agricultural by-products.
• Chemical Profile: Glycosidic compounds with amphiphilic properties (hydrophilic sugar moiety + hydrophobic sapogenin).
• Functional Properties: Natural surfactant and foaming agent, Cholesterol-binding and bioactive effects, Antimicrobial and antifungal activity, Hemolytic potential managed through formulation.
• Stability: Improved methods to enhance solubility and stability in various formulations.

Applications

• Food & Nutraceuticals: Natural cholesterol-lowering additives, functional beverages, and immune-boosting supplements.
• Pharmaceuticals: Vaccine adjuvants, anticancer, and anti-inflammatory agents.
• Cosmetics & Personal Care: Natural foaming agents in shampoos, soaps, and skincare products.
• Industrial Uses: Eco-friendly detergents, emulsifiers, and biocontrol agents in agriculture.

Advantages

• Natural and sustainable alternative to synthetic additives.
• Multifunctional activity (health + industrial value).
• Market potential in multiple high-growth sectors.

Collaboration Opportunities

We are seeking partnerships with:

• Pharma companies (pediatric oncology, RNA therapeutics).
• Clinical Research institutions (for preclinical & clinical validation).
• Investors (to accelerate translational development).

EXPORT INFO

Background

Ubiquitin is a small protein with regulatory function found in most tissues. It can be covalently attached to substrate proteins (known as ubiquitination) and affects their function in different ways: 1) alter cellular location, 2) affect activity, 3) prevent interaction with other proteins or molecules and 4) mark them for degradation. Enzymes that mediate ubiquitination are involved in a multitude of human diseases such as cancer, rheumatoid arthritis, and neurodegeneration. The wide-ranging study of ubiquitination in cellular and molecular biology makes “ubiquitin binding polypeptides” or “UBITRAPS” a "must-have tool" for the daily activity of many research laboratories.

Current Options. Most of the current options for the isolation of ubiquitylated proteins involve the overexpression of a tagged-ubiquitin moiety. This overexpression might influence the ubiquitination dynamics in the cells. By contrast, the ubiquitin binding polypeptides constitute a non-invasive method. The use of ubiquitin-specific antibodies is also a non-invasive technique, but the associated expenses and expertise required for their use are prohibitive for many laboratories.

Technology

The technology is based on the linkage of multiple ubiquitin interacting motifs connected via flexible linkers, resulting in molecular “traps” with high affinity for polyubiquitin. UBITRAPS have increased affinity and specificity for ubiquitinated proteins and facilitate further analysis. The UBITRAPS can be used in vitro as a solid support for purification of ubiquitinated proteins, but also a tool to capture modified proteins from living cells and tissues. These ubiquitin binding peptides may also protect poly-ubiquitinated proteins from the action of deubiquitinating enzymes, therefore increasing yield.

Application

Our technology can be used for:

• Detection, characterization and isolation of polyubiquitinated proteins from cells and tissues for analysis, especially for proteomic studies.
• Enrichment of linear-polyubiquitinated proteins (not possible with most tagged-ubiquitins).
• Development and implementation of novel screens for biomarkers and potential for diagnostic.

Advantages

• Low nanomolar dissociation constant for chains of polyubiquitin.
• 1000 to 10,000-fold higher specificity for polyubiquitin chains over ubiquitin monomers.
• Overexpression of epitope-tagged ubiquitin for pulldowns is not necessary.
• Flexible applications and compatible with commonly used isolation technologies.
• Technology can be applied to cells/tissues derived from patients and/or animal models.

Collaboration Opportunities

We are seeking partnerships with:

• Co-development of diagnostic kits and genome-editing tools.
• Licensing opportunities for therapeutic and diagnostic applications.
• Joint research projects on novel Cas variants.

EXPORT INFO